Thrombocytopenia Induced by Imatinib Mesylate (Glivec) in Patients with Chronic Myelogenous Leukemia: is 400 mg Daily of Imatinib Mesylate an Optimal Starting Dose for Japanese Patients?
- 1 January 2003
- journal article
- Published by Springer Nature in International Journal of Hematology
- Vol. 77 (1) , 93-95
- https://doi.org/10.1007/bf02982610
Abstract
No abstract availableKeywords
This publication has 2 references indexed in Scilit:
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001